Lipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Monday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners began coverage on shares of Lipocine in a report on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target on the stock.

Lipocine Trading Down 9.0 %

NASDAQ LPCN opened at $4.74 on Monday. Lipocine has a 12-month low of $2.44 and a 12-month high of $11.79. The company has a fifty day simple moving average of $5.17 and a two-hundred day simple moving average of $5.49. The stock has a market cap of $25.35 million, a P/E ratio of -6.24 and a beta of 1.24.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. As a group, sell-side analysts forecast that Lipocine will post -0.78 earnings per share for the current year.

Hedge Funds Weigh In On Lipocine

A hedge fund recently bought a new stake in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in shares of Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned approximately 0.22% of Lipocine as of its most recent filing with the Securities and Exchange Commission (SEC). 9.11% of the stock is currently owned by institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.